United Therapeutics's total inventories for the quarter that ended in Mar. 2026 was $178 Mil. United Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $181 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. United Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $39.47.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
United Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was 123.60.
Inventory Turnover measures how fast the company turns over its inventory within a year.
United Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.74.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
United Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.23.
United Therapeutics (NAS:UTHR) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
United Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
United Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
United Therapeutics Total Inventories Related Terms
United Therapeutics Total Inventories Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
United Therapeutics (UTHR) has a Total Inventories of $178 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for United Therapeutics and its competitors.
Is United Therapeutics' Total Inventories too high?
United Therapeutics' current Total Inventories is $178 Mil. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Total Inventories compare to VTRS and NBIX?
United Therapeutics' Total Inventories of $178 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for United Therapeutics and its competitors. United Therapeutics's current Total Inventories is $178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.36, compared to a current price of $554.59 — trading 43.5% above its estimated fair value. The current Total Inventories is $178 Mil. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Total Inventories is $178 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $554.59 is trading 43.5% above its estimated GF Value™ of $386.36.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
Total Inventories: $178 Mil
GF Value™: $386.36 vs. price of $554.59 (43.5% above fair value)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
